Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer
Study Information
Alliance Study ID: NCCTG-963255
NCT Study ID (ClinicalTrials.gov): NCT00003351
Disease or Cancer Type: Breast Cancer
Alliance Study Chair: Edith A. Perez, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of irinotecan in treating patients who have refractory metastatic breast cancer.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information